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ABSTRACT: Prospective anticancer metallodrugs should consider target-specific
components in their design in order to overcome the limitations of the current
chemotherapeutics. The inclusion of vitamins, which receptors are overexpressed in
many cancer cell lines, has proven to be a valid strategy. Therefore, in this paper we
report the synthesis and characterization of a set of new compounds [Ru(η5-
C5H5)(P(C6H4R)3)(4,4′-R′-2,2′-bpy)]+ (R = F and R′ = H, 3; R = F and R′ = biotin,
4; R = OCH3 and R′ = H, 5; R = OCH3 and R′ = biotin, 6), inspired by the
exceptional good results recently obtained for the analogue bearing a triphenylphos-
phane ligand. The precursors for these syntheses were also described following
modified literature procedures, [Ru(η5-C5H5)(P(C6H4R)3)2Cl], where R is −F (1) or
−OCH3 (2). The structure of all compounds is fully supported by spectroscopic and
analytical techniques and by X-ray diffraction studies for compounds 2, 3, and 5. All
cationic compounds are cytotoxic in the two breast cancer cell lines tested, MCF7 and
MDA-MB-231, and much better than cisplatin under the same experimental conditions. The cytotoxicity of the biotinylated
compounds seems to be related with the Ru uptake by the cells expressing biotin receptors, indicating a potential mediated
uptake. Indeed, a biotin−avidin study confirmed that the attachment of biotin to the organometallic fragment still allows biotin
recognition by the protein. Therefore, the biotinylated compounds might be potent anticancer drugs as they show cytotoxic
effect in breast cancer cells at low dose dependent on the compounds’ uptake, induce cell death by apoptosis and inhibit the
colony formation of cancer cells causing also less severe side effects in zebrafish.
■ INTRODUCTION
One of the main obstacles in the development of new
anticancer drugs is the lack of selectivity toward cancer cells
that leads to undesirable side effects. Therefore, the design of
target-specific drug delivery systems is still a very relevant
challenge. An approach to this subject has been the use of
vitamin−drug conjugates as a vehicle for a vitamin-mediated
drug targeting due to the overexpression of vitamin receptors
in the surface of cancer cells. In this frame, folic acid (vitamin
B9), cobalamin (vitamin B12), riboflavin (vitamin B2), and
biotin (vitamin B7) have been tested.1−6 In particular, biotin
has attracted more attention in the last years due to its higher
tumor specificity imparted by its receptor-mediated uptake.7
The main biotin transporter is the sodium-dependent multi-
vitamin transporter (SMVT) that is overexpressed in several
cancer cell lines such as breast MCF7 and MDA-MB-231,5
thus supporting the relevance on the use of biotin as a
targeting agent.
Several known anticancer agents in clinical use, such as
paclitaxel,8 doxorubicin,9 and gemcitabine,10 have been
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functionalized with biotin to improve their efficiency and
efficacy while reducing their toxicity.6
Furthermore, a prospective Pt(IV) prodrug (Figure 1a)
based on cisplatin scaffold and bearing biotin and the
nonsteroidal anti-inflammatory drug indomethacin (biotin-
Pt(IV)-indomethacin conjugate) showed selectivity toward
cancer cells vs. normal cells, while being cytotoxic and effective
against cisplatin-resistant cancer cells.11 The inclusion of biotin
lead to a substantial increase in Pt uptake by the cells relative
to cisplatin demonstrating a possible promotion of the
compound’s uptake via biotin receptor-mediated pathway.
However, there is not a direct correlation with cytotoxicity.
Nowadays, ruthenium compounds are established alter-
natives to platinum-based drugs, trying to overcome their
limitations in terms of toxicity and low efficacy for certain types
of cancers. In this frame, some prospective ruthenium(III)
compounds have reached clinical trials.12−14
The search for ruthenium(II) organometallic compounds is
also an attractive option for medicinal chemistry due to the
structural variety, chemical stability, diverse ligand bonding
modes and redox properties achievable. Much of the literature
is dedicated to the piano stool ruthenium(II)−(η6-C6H6)
derivatives developed by Dyson,15 Sadler,16 and co-workers.
These compounds have shown good cytotoxicity in vitro and
ability to reduce primary tumors in vivo, presenting in some
cases antimetastatic activity as well. Also, the family of piano
stool ruthenium(II)−(η5-C5H5) derivatives has been attracting
attention by some research groups due to their important
cytotoxicity both in vitro17,18 and in vivo.19,20
Targeting approaches using biotin have been also reported
as, for example, the work by Hartinger and co-workers, where
half-sandwich ruthenium(II) biotin conjugates (Figure 1b)
were tested against colon cancer cell lines with higher levels of
SMVT (SW620 cells presents ∼3 times more SMVT than
HCT166 and COLO-205 cells).21 However, no direct
correlation between the biotin conjugation and the cellular
Ru content and cytotoxicity was observed, implying that
alternative pathways for cellular uptake of this compound
might be operating.21 Bonnet and co-workers also recently
reported on a family of [Ru(tpy)(bpy)(SRR′)](PF6)2
complexes, where, for the most promising approach, SRR’ is
a symmetrical ligand containing two identical biotin moieties
linked via a triethylene glycol spacer (Figure 1c).22 The
authors proved that the compound binding to streptavidin is
about the same as the natural biotin. The photochemical
release of the SSR’ ligand from the complex occurs upon blue
Figure 1. Prospective metallodrug−biotin conjugates.
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light irradiation, independent of the binding to streptavidin,
thus envisaging their use as photoactivated chemotherapeutic
complexes in streptavidin-mediated targeted therapy.
We have been interested in exploring the potential of
ruthenium(II)−(η5-C5H5) derivatives.20,23−27 During our
structure−activity studies we have noticed that the compounds
belonging the family with the general formula [Ru(η5-
C5H5)(2,2′-bipyridine)(phosphane)]+ were those with the
best cytotoxicities against several human cancer cell lines and
also the most stable under physiological conditions.17,23
Recently, we described the conjugation of biotin to a
ruthenium(II)-cyclopentadienyl compound of this family
(Figure 1d).28 This complex was cytotoxic against MCF7
and MDA-MB-231 breast cancer cell lines and showed
exceptional selectivity as P-gp inhibitor and good tolerability
for zebrafish (up to 1.17 mg/L at 5 days post fertilization). In
the present study we synthesized a family of related
compounds bearing different functional groups at the
phosphane ligand to investigate their influence on cytotoxicity,
cellular uptake via receptor mediated internalization and in vivo
toxicity in zebrafish.
■ RESULTS AND DISCUSSION
On the basis of the successful results in biological activity we
recently obtained28 for a biotinylated ruthenium−cyclo-
pentadienyl complex (LCR134, Figure 1), an enlarged family
of compounds was explored. Here, the chemical and biological
responses to the substitution on the triphenylphosphane
coligand were studied (Scheme 1). The starting materials
with the general formula [Ru(η5-C5H5)(P(C6H4R)3)2Cl],
where R is −F (1) or −OCH3 (2), were synthesized following
a modified literature procedure29,30 giving orange crystalline
powders in 67% and 51% yield, respectively. As for the cationic
complexes [Ru(η5-C5H5)(P(C6H4R)3)(4,4′-R′-2,2′-bpy)]+,
where R′ is −H (3 and 5) or biotin (4 and 6), the syntheses
were performed in reflux in dichloromethane (complexes 3 and
5) or methanol (complexes 4 and 6) for 4−7 h, by σ
coordination of the bipyridine chelating ligand using silver
triflate as chloride abstractor (Scheme 1). The orange
complexes were obtained in moderate to good yields (52−
87%).
The formulation and purity of all the new compounds is
supported by FT-IR, UV−vis, and 1H, 13C, and 31P NMR
spectroscopic data and elemental analyses.
The solid-state FT-IR spectra (KBr pellets) of the six new
organometallic ruthenium−cyclopentadienyl complexes show
the presence of the typical bands attributed to υCH stretching
of the phosphane, cyclopentadienyl, and bipyridyl ligands
(when present) in the range 3100−3000 cm−1 and the bands
for υCC at 1600−1475 cm−1. The presence of the triflate
counterion for the cationic complexes 3−6 was confirmed by
the typical signal for this group (∼1240 cm−1). For the
compounds bearing the bipy−biotin ligand the typical bands
attributed to υN−H and υC−N stretching of the amines (3500−
3300 cm−1 and 1200−1025 cm−1, respectively), as well as the
υCO stretching of the ester and ketone (1732 and ∼1700,
respectively), were also present. The υC−H stretching bands,
attributed to the alkyl chain of the bipy−biotin ligand, were
also observable at 2930−2860 cm−1.
Analysis of the overall 1H NMR data show that the
resonances of the η5-cyclopentadienyl ring are in the
characteristic range for neutral and monocationic ruthenium-
(II) complexes (at 4.09−4.22 and 4.89−4.97 ppm, respec-
tively). The successful coordination of the bipyridyl derivatives
is supported by the deshielding of the H1 protons (∼0.85
ppm) and a shielding of the H4 protons (0.25−0.32 ppm).
Additionally, the resonances of the phosphane coligands
appear between 6.66 and 7.49 ppm, being more shielded for
the compounds bearing the -OCH3 due to its electron
donating character. The 31P NMR spectra showed a unique
sharp singlet for all the compounds, with the expected
deshielding behavior upon coordination. The most shielded
31P NMR signal is observed for compounds 5 and 6 containing
4-(methoxyphenyl)phosphane, due to the presence of the
−OCH3 group in the para position of the benzene ring, which
agrees with the 1H NMR data described above. The
APT-13C{1H} and 13C{1H} NMR data are in accordance
with the aforementioned effects in the 1H NMR analysis.
The optical absorption spectra of complexes 1−6 and
bipyridyl ligands were recorded in 10−4 to 10−6 M in
dichloromethane and dimethyl sulfoxide solutions. In dichloro-
methane all the compounds present an intense band below 250
nm attributed to π−π* transitions occurring at the organo-
metallic fragment {RuCp(P(C6H4R)3)}
+. Relatively to the
Scheme 1. Synthetic Route of the New Ru(II) Complexesa
aCompounds are numbered for NMR assignments.
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compounds bearing the bipyridyl derivatives a second strong
absorption band, appearing at ∼290 nm, is attributed to the π
→ π* transitions that take place in the coordinated bipyridyl
derivatives (Figure 2a). In addition to these bands, two
maximum absorptions, at ∼420 and ∼480 nm were found for
complexes 3 and 4, and at ∼430 and 490 nm for complexes 5
and 6, were attributed to metal-to-ligand charge transfer bands
(MLCT), from Ru 4d orbitals to π* orbitals of N-
heteroaromatic rings and to phosphane, as previously reported
for related compounds.23,31,32
Electronic spectra in DMSO were performed in order to
infer about the charge transfer character of these bands. A
hypsochromic shift of ca. 5 nm at the MLCT band can be
observed, confirming the charge transfer nature of it, as
exemplified in Figure 2b for compound 6.
X-ray Crystal Structure Determination. Single crystal
structures of mononuclear species of [Ru(η5-C5H5)(P-
(C6H4OCH3)3)2Cl] (2), [Ru(η
5-C5H5)(P(C6H4F)3)(bipy)]-
[CF3SO3] (3), and [Ru(η
5-C5H5)(P(C6H4OCH3)3) (bipy)]-
[CF3SO3] (5) are reported in this work. A dinuclear minor
species obtained during the recrystallization processes of
LCR134 where the biotin ligand acts as bridge between two
Ru ions was also obtained, {[Ru(η5-C5H5)Cl]-μ(N,N-biotin-
S,S)-[Ru(η5-C5H5)(P(C6H5)3)]}[Cl(CF3SO3)] (LCR134′).
Compounds 2, 3, and 5 crystallize from the solutions as red
blocks. Figure 3a−c shows ORTEP representations of 2, 3, and
5, respectively. In LCR134′, the asymmetric unit contains a
dinuclear ruthenium cation complex, one (CF3SO3)
− and one
Cl− anion, which is disordered and occupies two positions in
the crystal packing. Figure 3d shows an ORTEP representation
of the dinuclear complex.
In the four molecular structures, the ruthenium center
adopts a “piano stool” distribution formed by the ruthenium−
Cp unit bound to the different ligands.33 The distances for
Ru−P bonds are Ru(1)−P(1) = 2.3243(9) Å and Ru(1)−P(2)
= 2.3208(9) Å in 2, Ru(1)−P(1) = 2.3022(5) Å in 3 and
2.3220(5) Å in 5 and Ru(2)−P(1) = 2.3141(19) Å in
LCR134′ and the distances Ru−N bonds are Ru(1)−N(1) =
2.0719(14) Å in 3, 2.0827(14) Å in 5 and 2.074(8) Å in
LCR134′ and Ru(1)−N(2) = 2.0910(15) Å in 3, 2.0920(14)
Å in 5 and 2.055(7) Å in LCR134′. The distance between Ru
and the centroids of the π-bonded cyclopentadienyl moiety are
Figure 2. Electronic spectra of (a) 3 (), 4 (−−), 5 (---) and 6 (−) in dichloromethane solutions. Expansion of the spectra in the region of
the CT transitions (b) 6 in DMSO (dashed line) and in dichloromethane (solid line) solutions, showing the hypsochromic shift.
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1.8516(2) Å in 2, 1.8318(1) Å in 3, 1.8383(1) Å in 5 to Ru
center, and 1.837(5) Å to Ru(1) and 1.852(4) to Ru(2) in
LCR134′, (ring slippage 0.033 Å in 2, 0.029 Å in 3 and 0.046
Å in 5, 0.061 and 0.065 Å in LCR134′). The mean value of the
Ru−C bond distance is 2.2096(30) Å for 2, 2.1960(17) Å for
3, 2.2015(17) Å for 5 and 2.181(9) and 2.207(8) Å for
LCR134′. Table S1 in Supporting Information contains
selected bond lengths and angles for the four compounds.
X-ray structure analysis of the structures show two
enan t iomer s o f the comp lex [Ru(η 5 -C5H5)(P -





+, which are present in the racemic
crystals. The chirality is the result of a twist of the PPh3 and
Cp. The complexes show a mirror plane containing P, Ru and
the centroid of Cp rings (see Figure S1).23,34 LCR134′
crystallizes in a chiral space group C2 and only contains one
species. The Flack parameter of 0.04(5) confirms this fact.35
Stability Studies in Aqueous Media. Studies in aqueous
relevant media of the new bipyridine-based compounds were
performed prior to in vitro evaluation in order to access their
stability. Thereby, complexes 3−6 were tested in culture
cellular media over 24 h using 5% DMSO as cosolvent, by
UV−vis spectroscopy (Figure S2). DMSO is used in the
biological assays to allow complete solubilization of the
compounds. All the complexes showed adequate stability
over time, allowing their further biological study.
Biological Evaluation of the Compounds. Analysis of
the Cytotoxicity in Breast Cancer Cell Lines. The cytotoxic
activity of compounds 3−6 and the phosphane and bipyridine-
based ligands was assessed in two human breast cancer cell
lines, MCF7 and MDA-MB-231, at 24 h, using the colorimetric
MTT assay. These cell lines were selected considering their
different responses to cisplatin (CDDP) and their different
genetic profiles. While MCF7 cell line has functional estrogen
(ER α+) and EGF receptors and is noninvasive, MDA-MB-231
cells are hormone-independent, showing the triple negative
phenotype (ER-, PR-, HER2-) being more invasive. Cells were
treated with the compounds within the concentration range of
0.01−100 μM (or 10−200 μM for the ligands), and to CDDP
within the concentration range 10−150 μM, for a period of 24




bipy-4,4′-dibiotin ester)][CF3SO3] (LCR134), and CDDP
were also included for comparison (Table 1). We could
observe that the organometallic compounds showed low IC50
levels in the two cell lines tested, being much more cytotoxic
than the organic ligands per se, showing that the cytotoxicity of
the complexes results from a synergy between all coligands and
the metal center. The complexes bearing the 2,2′-bipyridine
Figure 3. ORTEP for compounds (a) 2, (b) 3, (c) 5, and (d) LCR134′. All the non-hydrogen atoms are presented by their 50% probability
ellipsoids. Hydrogen atoms are omitted by clarity.
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ligand (3 and 5) are the most cytotoxic, similar to TM34 for
both cell lines. Compounds 4 and 6, bearing the bipy−biotin
ligand, are also cytotoxic for both cell lines and of the same
order of magnitude as LCR134. All compounds exhibit lower
IC50 values than CDDP by ∼2−42 fold for MCF7 and ∼9−87
fold for MDA-MB-231 cell line, and are generally better or in
the same order of magnitude of other Ru(II)−η6-arene
derivatives.36−44 Thus, the results suggest that these com-
pounds might be potent anticancer drugs as the dose that show
cytotoxic effect is low. Interestingly, the compounds bearing
the bipy−biotin based ligand are more cytotoxic for the most
invasive MDA-MB-231 cell line, which may be related to their
cellular uptake and the different genetic background of these
cells, and these differences may affect the sensitivity of the cells
to the compounds. In fact, a recent paper by Sava and co-
workers discloses that, for RAPTA-T ([Ru(η6-C6H5Me)(pta)-
Cl2], pta = 1,3,5-triaza-7-phosphaadamantane), the differences
in activity obtained between MCF7 cell line and the invasive
MDA-MB-231 might be related to the antimetastatic proper-
ties observed for this compound for which the MDA-MB-231
cell line is a good model.45
Biotin−Avidin Interaction Assay. The relative affinity of
compounds 3−6 and LCR134 to avidin was determined by
using a Biotin Quantitation Kit. The compounds and biotin
(used as positive control) were added to a solution containing
a mixture of HABA (4′-hydroxyazobenzene-2-carboxylic acid)
and avidin. Because of its higher affinity for avidin, biotin (or
biotinylated compounds) displaces HABA and the absorbance
at 500 nm decreases proportionately. As expected, the affinity
for avidin was higher for the natural ligand biotin. Regarding
the ruthenium compounds, all the biotinylated compounds
(LCR134, 4, and 6) showed an affinity for avidin that was
approximately half of the one showed by biotin, while the
nonbiotinylated compounds (3 and 5) did not interact. The
values do not differ significantly among the biotinylated
compounds tested, suggesting that the presence of the different
phosphane coligands do not interfere with biotin recognition.
The recognition of biotin-based complexes by avidin indicates
that this synthesis approach used to target the biotin
transporter (SMVT) is valid, as already observed for other
ruthenium organometallic compounds.21
In Vivo Toxicity Assessment Using Zebrafish Embryos.
The zebrafish (Danio rerio) model has been considered an
attractive and viable alternative model to study human
diseases, complementary to rodent models, due to zebrafish
ease of husbandry and more affordable maintenance. Zebrafish
develop very rapidly and have high fecundity and fertilization
rates (up to 200 fertilized eggs per mating pair) compared to
mammalian models (5−10 offspring per mating pair), reducing
the time needed to complete a study. Furthermore, the
zebrafish genome shows approximately 70% of homology with
the human genome and 82% of orthologous (derived from a
common ancestral sequence) human disease-related genes.48,49
Thus, the zebrafish embryo larval assay (ZELA) was used for
evaluating adverse effects of chemical exposure of complexes
3−6 at the organ system level and for that, a modified
OECD.2013 protocol was used.50 At 3 h post fertilization
(hpf), eggs were exposed to increasing concentrations of these
complexes. The fertilization rate was >80% and the control
survival rate was consistently ≥90%. The compound
concentrations were analytically evaluated by ICPMS at the
end of the experiment, and they are shown in the Experimental
Section. Daily observations of the embryos were recorded and
lethality/survival, as well as lesions, were evaluated.
From the dose response curves, four acute toxicity end
points were obtained: LC50, lethality for 50% of the embryos/
larvae; NOEC, no observed effect concentration; LOEC,
lowest observed effect concentration; and NOEL, no observed
effect level (Table 2).
Graphical representations of the lethality-response curves for
each complex can be seen in Figure 4 and allowed for the
estimation of the LC50 values at the end of 120 hpf experiment.
At first glance, it appeared that 3 is the least toxic of this series
of compounds, having the highest LC50 value. Its major toxic
lesion however is necrosis, as can be seen in Table S2
(moderate to severe effect), causing severe damage (cellular
lysis) to the embryos and eventually their death. This process,
contrarily to apoptosis, is caused by external factors and results
in premature death of cells in living tissues and was only found
for complexes 3 and 5, which have the 2,2′-bipyridine ligand.
Complexes 4 and 6, bearing the 2,2′-bipy-4,4′-dibiotin ester
ligand, had essentially yolk sac edema and pericardial sac
edema (moderate to severe); for complex 4, hemorrhage of the
syncytial layer was also observed. The yolk syncytial layer is a
Table 1. IC50 Values (μM) for Complexes 3−6, TM34,
LCR134, CDDP, and Phosphane and Bipyridine-Based
Ligands at 24 h Incubation, in MCF7 and MDA-MB-231
Breast Cancer Cells (n.d.: Not Determined)
compound MCF7 (μM) MDA-MB-231 (μM)
TM34 0.9 ± 0.346 1.5 ± 0.347
3 0.9 ± 0.3 2.1 ± 0.6
5 1.7 ± 0.5 1.4 ± 0.4
LCR134 22.5 ± 1.8 10.6 ± 0.3
4 22.4 ± 1.6 14.2 ± 0.7
6 18.7 ± 1.6 7.7 ± 0.3
CDDP 37.9 ± 1.428 122.3 ± 24.928
triphenylphosphane 143.5 ± 31.6 176.0 ± 35.5
tris(4-fluorophenyl)phosphane 101.0 ± 22.0 185.9 ± 14.7
tris(4-methoxyphenyl)phosphane 198.1 ± 67.3 161.9 ± 25.8
2,2′-bipyridine n.d. 125.1 ± 21.3
2,2′-bipy-4,4′-dibiotin ester n.d. >200
Table 2. Estimates Obtained from in Vivo Toxicity Analyses at the End of the 120 hpf Experiment
LC50 (95% CL
a) (mg/L) NOEC (mg/L) LOEC (mg/L) NOEL (mg/L) NOEL (ng/larvae)
3 3.28 (2.50−3.72) − 2.02 0.69 1.56
4 2.35 (2.09−2.48) − 1.31 − −
5 0.80 (0.35−1.16) 0.17 0.57 0.17 0.92
6 1.83 (1.28−2.17) − 1.52 0.80 1.17
LCR13428 5.73 (4.74−6.26) 2.18 3.48 1.17 2.34
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highly dynamic syncytial tissue with essential and diverse
functions during early zebrafish development. Damage in this
cellular structure may indicate that the embryonic develop-
ment is compromised. The most frequently observed grossly
visible effects are summarized in Figure 5 and Tables S2−S5.
At the end of the experiment (120 hpf), the larvae were
sacrificed, digested, and analyzed by ICPMS to quantify the Ru
(Figure S3). Complex 3 had the highest internalization rate in
the larvae (4.93 ng/larvae), followed by complex 4 and 5, with
3.79 and 3.57 ng/larvae, respectively, that are in the same
range of magnitude of LCR134. Complex 6 had the lowest
internalization rate (1.17 ng/larvae).
Intraocular distance, total body length, pericardial sac, and
yolk sac area end points were analyzed to better describe the
adverse morphometric effects (Figures S4−S7). All complexes
showed reduced body length for either all concentrations (4
and 6) or for the two highest concentrations (3 and 5), which
may be an indication of an inhibition of the overall growth of
the organism.
Intraocular distance was used to indicate changes in cranio-
facial development following embryonic chemical exposure. A
significant decrease of intraocular distance was found for 4 (all
concentrations), 5 (0.17; 0.57 mg/L), and 6 (1.52 mg/L).
The yolk sac comprises vitellogenin derived yolk-proteins
that entirely support nutritional needs of the embryo/larvae
prior to beginning feeding after 120 hpf. Thus, its size is a
significant end point in assessing whether the compound
affected the magnitude of the available nutrients and their use
in embryonic zebrafish. It was observed that the yolk sac size
has only increased with exposure to complexes 3 and 4, which
may indicate either fluid accumulation outside the vasculature
(yolk sac edema) and/or an uptake of lipoproteins.
Finally, the pericardial sac size was also measured, revealing
that there was only a statistically significant increase of the
pericardial sac size for one of the concentrations of complex 4
(1.79 mg/L). In fact, this complex was the only one showing a
mild to moderate level of pericardial sac edema for almost all
concentrations, possibly indicating that it may have compro-
mised the cardiovascular system of the embryos.
Since that compounds 3 and 5 showed severe toxic effects
(necrosis/cell lysis) compared to the biotinylated complexes 4,
6, and LCR134 (major lesions were yolk sac and pericardial
sac edemas), one can consider that the targeting approach was
successful leading to better in vivo tolerability. Thus, these
three compounds bearing the 2,2′-bipy-4,4′-dibiotin ester
ligand were selected for further studies aiming to understand
their anticancer properties.
Intracellular Distribution of the Ruthenium Complexes.
The intracellular distribution of the complexes 4, 6 and
LCR134 was performed using MCF7 and MDA-MB-231 cells,
both expressing biotin receptors,5 following exposure to each
complex for 24 h at a concentration equivalent to their IC50
values. Cytosol, membrane, nucleus, and cytoskeletal fractions
were extracted using a commercial kit as described in the
Figure 4. Lethality-response curves for tested ruthenium complex solutions in mg/L (A, complex 3; B, complex 4; C, complex 5; and D, complex
6).
Figure 5. Representative pictures of zebrafish lesions found after
treatment with complexes 3−6. Key: (A) necrosis; (B) hemorrhage in
syncytial layer; (C) yolk sac edema and pericardial sac edema; (D)
control (stained). The zebrafish embryos representative pictures were
obtained with Olympus SZ-PT dissecting microscope equipped with
Scion digital camera model CFW-1310C and analyzed with
Photoshop software. Magnification 4×.
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Experimental Section. In general, all the compounds are mainly
retained at the membrane of both cancer cell lines (Figure 6;
>90% for MDA-MB-231 and >75% for MCF7). Similar trends
were observed for related ruthenium cyclopentadienyl
compounds previously reported.47,51 For the MDA-MB-231
cell line, the cytotoxicity of the compounds correlates well with
their internalization being higher for complex 6, followed by
LCR134 and 4. For the MCF7 cell line an increase in the Ru
content on the cytosol fraction was observed (16% for
LCR134, 9% for 4, and 7% for 6). These results might be
related to the different genetic background of each cell line.
For this cell line, the cytotoxicity does not correlate with the
Ru uptake by the cells. Normalizing the results for the
concentration administered in each condition (Figure S8), one
can observe that the total ruthenium content is approximately
the same in both cell lines for LCR134 and complex 4, while
Figure 6. Cellular Ru distribution in the MCF7 and MDA-MB-231 cells treated with the compounds LCR134, 4, and 6 at a concentration
equivalent to the IC50 values found at 24 h challenge, 37 °C. Results are expressed in ng of Ru per million of cells (a and b) or in total percentage (c
and d). Results are expressed as mean ± SD of two independent experiments.
Figure 7. Ruthenium-based compounds potentiate apoptotic cell death in breast cancer cell line. Apoptotic cell death was analyzed by Annexin V
fluorescein isothiocyanate (AV-FITC) and propidium iodide (PI) assay in MDA-MB-231 cells, after incubation with IC50 and 2 × IC50
concentrations for 48 h. Cisplatin was used as a positive control at a concentration of 40 μM and 80 μM. (a) Graphical representation of the
Annexin V/PI dot plots of flow cytometry data of control, CDDP, LCR134, 4, and 6 compounds were analyzed using Flowing software. Values are
mean ± SD of three independent experiences. (b) Percentages of apoptotic cells (positive for AV). Values represent mean ± SD of at least three
independent experiments. Statistical analysis was performed by one-way ANOVA with Dunnett′s multiple comparisons test. Key: (∗∗) P ≤ 0.01;
(∗∗∗) P ≤ 0.001; (∗∗∗∗) P ≤ 0.0001 compared with negative control.
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for compound 6 the Ru content in the MDA-MB-231 cell line
is approximately 9 times higher than in the MCF7 cell line,
showing that the phosphane coligand also has a role on the
cellular uptake of these compounds.
Evaluation of the Cell Death Mechanism Induced by
Ruthenium-Based Compounds. Annexin V/Propidium iodide
(AV/PI) cytometry-based assay was used to determine the cell
death mechanism caused by the ruthenium compounds. MDA-
MB-231 cells were incubated with the ruthenium compounds
LCR134, 4, and 6 for 48 h at their IC50 and 2 × IC50 values
(Table S6). Cisplatin was used as positive control. The results
showed that the compounds induce apoptosis instead of
necrosis and that the majority of the cells appear at early
apoptosis (Figure 7). Excluding the IC50 conditions of
LCR134 and of complex 6, all the other conditions
significantly induced apoptosis at higher levels.
The Effects of Biotin-Based Compounds in the Colony
Formation Potential of Cancer Cells. To evaluate the colony
formation potential of the most promising compounds
LCR134, 4 and 6, MDA-MB-231 breast cancer derived cell
line were exposed to 1/4 of the IC50 and IC50 values of the
different compounds for 48 h, after which the medium was
removed, and cells were maintained in culture for 11 days.
MDA-MB-231 breast cancer derived cell line is commonly
used as a model of Triple Negative Breast Cancer (TNBC).
TNBC typically encompasses highly metastatic cancers with
poorer prognosis to which no available effective therapy is
available yet.52 Our results showed that all the compounds
reduce the ability of the cells to form colonies (Figure 8). All
concentrations of compounds studied, except 1/4IC50 of
complex 6, have significantly prevented the formation of
colonies, and under conditions treated with the IC50 values, the
compounds inhibited the ability to form colonies in a high
extent. Regarding to LCR134 compound, the results were very
promising, since at the 1/4 IC50 and IC50 concentrations, the
compound almost completely inhibited the formation of
Figure 8. Colony formation ability of MDA-MB-231 after being exposed to our compounds. Analysis of the clonogenic ability, after 48 h
incubation with 1/4 IC50 and IC50 values, in MDA-MB-231 cell line. CDDP was used as a positive control at 10 and 40 μM. (a) Representative
images of colony formation assay in MDA-MB-231 cell line. (b) Values represent mean ± SD of at least three independent experiments. Statistical
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colonies, which was very similar to the results of cisplatin. This
is a very good result since cisplatin is one of the most
chemotherapeutic agents used in the treatment of this type of
cancer, although it has severe side effects and acquisition of
resistance.53 Interestingly, the IC50 value of LCR134 inhibited
completely the formation of colonies but did not induce
apoptosis in a significant manner, which could suggest that this
compound has a mechanism of action with greater action in
inhibiting proliferation rather than inducing cell death.
■ CONCLUSIONS
A family of new compounds with the general formula [Ru(η5-
C5H5)(P(C6H4R)3)(4,4′-R′-2,2′-bpy)]+ (R = F and R′ = H, 3;
R = F and R′ = biotin, 4; R = OCH3 and R′ = H, 5; R = OCH3
and R′ = biotin, 6, R = H, R′ = biotin, LCR13428) was
synthesized. The precursors [Ru(η5-C5H5)(P(C6H4R)3)2Cl]
(R = F, 1 or R = OCH3, 2) were also prepared following
modified literature procedures. All the compounds were
completely characterized by spectroscopic and analytical
techniques and by X-ray diffraction studies for compounds 2,
3, and 5. While all the cationic complexes showed
cytotoxicities much better than cisplatin in the breast MCF7
and MDA-MB-231 cancer cell lines, none of the organic
ligands was cytotoxic for the cell lines tested. Importantly, for
the biotinylated compounds, there is a relation between Ru
uptake by the cells and the cytotoxicity for the most aggressive
and invasive MDA-MB-231 cell line. All biotinylated
compounds were recognized by avidin, even if it was at
lower extent than the natural avidin, showing that the
recognition was not greatly affected upon complexation and
indicating that biotin might act as a biological vector
promoting the delivery of the compounds to the cells.
Overall, the biotinylated compounds can be considered
promising anticancer drugs since they show low IC50 values,
induce cell death by apoptosis and inhibit the colony formation
of cancer cells being better tolerated in zebrafish than the
nonbiotinylated compounds. The fact that the biotinylated
compounds are (i) more active for the invasive MDA-MB-231
cell line than to the MCF7 cell line, (ii) mainly retained at the
cell membrane of cancer cells (>90% for MDA-MB-231), and
(iii) able to inhibit the formation of colonies (loss of adhesive
interactions) might forecast an antimetastatic behavior as was
reported for other ruthenium compounds.45
■ EXPERIMENTAL SECTION
General Procedures. All reactions and manipulations were
performed under nitrogen atmosphere using Schlenk techniques. All
solvents used were dried and freshly distilled under nitrogen prior to
use, using standard methods. 1H, 13C, and 31P NMR spectra were
recorded on a Bruker Avance 400 spectrometer at probe temperature
using commercially available deuterated solvents. 1H and 13C chemical
shifts (s = singlet; d = doublet; t = triplet; m = multiplet, dd = doublet
of doublets, dt = doublet of triplets) are reported in parts per million
(ppm) downfield from internal standard Me4Si, and the
31P NMR
spectra are reported in ppm downfield from external standard, 85%
H3PO4. Coupling constants are reported in Hz. All assignments were
attributed using APT-13C{1H} or 13C{1H}, COSY, HMBC and
HMQC NMR techniques. Infrared spectra were recorded on KBr
pellets using a Mattson Satellite FT-IR spectrophotometer and only
relevant bands were cited in the text. Electronic spectra were obtained
at room temperature on a Jasco V-560 spectrometer from solutions of
10−4−10−6 M in quartz cuvettes (1 cm optical path). Elemental
analyses were performed at Laboratoŕio de Anaĺises, at Instituto
Superior Tećnico, using a Fisons Instruments EA1 108 system. Data
acquisition, integration, and handling were performed using a PC with
the software package EAGER-200 (Carlo Erba Instruments).
The synthesis of the bipy−biotin ligand was previously described
by us.28
Synthesis. [Ru(η5-C5H5)(P(C6H4R)3)2Cl], R = F (1) or OCH3 (2).
The synthesis of 1 has been previously described in the literature.29
Here we report slight alterations and a complete characterization. The
synthesis of 2 is new and was adapted from the literature.30 To a
stirred and degassed solution of hydrated ruthenium trichloride (0.33
g, 1.59 mmol; 2.32 g, 11.20 mmol for 1 and 2, respectively) in ethanol
(60 mL) was added tris(4-fluorophenyl)phosphine or tris(4-
methoxyphenyl)phosphine (1.83 g, 5.80 mmol; 10.00 g, 28.00
mmol for 1 and 2, respectively) and freshly distilled cyclopentadiene
(4 mL; 20 mL, for 1 and 2, respectively). The dark brown mixture
obtained was refluxed with vigorously stirring for 7 or 4 h (for 1 or 2,
respectively) until no more precipitation of the orange complex was
observed. After refluxing, the mixture was cooled to room temperature
overnight. The precipitate was filtered, washed with water (2 × 20
mL), hexane, and light petroleum ether or diethyl ether (2 × 20 mL,
for 1 and 2, respectively). The crystalline orange powder obtained was
dried under vacuum, originating compounds 1 and 2 in 67% and 51%
yields, respectively. Single crystals were isolated by recrystallization
from dichloromethane/n-hexane for compound 2.
Complex 1. 1H NMR [(CD3)2CO, Me4Si, δ/ppm]: 7.49 (m, 12,
HmetaP(PhF)3); 7.01 (t, 12,
3JHH = 8.0, HorthoP(PhF)3); 4.22 (s, 5, η
5-
C5H5).
13C{1H} NMR [(CD3)2CO, δ /ppm]: 164.1 (d,
1JCF = 248.5,
Cq, P(PhF)3); 136.9 (dt,
3JCP = 5.9;
2JCF = 7.9, CHmetaP(PhF)3);
135.1 (dd, 1JCP = 41.8;
4JCF = 4.0, Cq, P(PhF)3); 115.5 (dt,
2JCP =
21.0; 3JCF = 5.1, CHorthoP(PhF)3); 82.6 (t,
2JCP = 2.0, Cp).
31P{1H}
NMR [(CD3)2CO, δ/ppm]: 38.17 (s, P(PhF)3). UV−vis [CH2Cl2,
λmax/nm (ε × 10
3/M−1cm−1)]: 234 (34.8); 291 (Sh); 369 (2.4); 454
(Sh). [DMSO, λmax/nm (ε × 103/M−1cm−1)]: 285 (Sh); 366 (2.1);
441 (Sh). FTIR [KBr, cm−1]: 3070, 3036 (υC−H Cp and phenyl
rings); 1587, 1494 (υCC Cp and aromatic rings). Anal Calcd for
C41H29ClF6P2Ru (834.14): C, 59.0; H, 3.5. Found: C, 58.6; H, 3.5.
Complex 2. 1H NMR [CDCl3, Me4Si, δ/ppm]: 7.30 (m, 12,
HorthoP(PhOCH3)3); 6.66 (d, 12,
3JHH = 12.0, HmetaP(PhOCH3)3);
4.09 (s, 5, η5-C5H5); 3.77 (s, 18, OCH3).
13C{1H} NMR [CDCl3, δ
/ppm]: 159.8 (Cq, P(PhOCH3)3); 135.3 (t,
2JCP = 5.5, CHorthoP-
(PhOCH3)3); 130.4 (d,
1JCP = 44.3, Cq, P(PhOCH3)3); 112.9 (t,
3JCP
= 5.0, CHmetaP(PhOCH3)3); 81.1 (m, Cp); 55.3 (OCH3).
31P{1H}
NMR [CDCl3, δ/ppm]: 35.67 (s, P(PhOCH3)3). UV−vis [CH2Cl2,
λmax/nm (ε × 10
3/M−1cm−1)]: 246 (68.6); 287 (Sh); 369 (2.8); 447
(Sh). [DMSO, λmax/nm (ε × 10
3/M−1cm−1)]: 380 (23.9); 446 (Sh).
FTIR [KBr, cm−1]: 3065 (υC−H Cp and aromatic rings); 1400−1600
(υCC Cp and aromatic rings). Anal Calcd for C47H47ClO6P2Ru
(906.35): C, 62.2; H, 5.2. Found: C, 62.0; H, 5.2.
[Ru(η5-C5H5)(P(C6H4R)3)(bipy)][CF3SO3] (R = F, 3; R = OCH3, 5).
To a stirred and degassed solution of 1 or 2 (0.20 g, 0.25 mmol; 0.13
g, 0.14 mmol, respectively) in dichloromethane (40 mL) were added
2,2′-bipyridine (0.05 g, 0.29 mmol; 0.03 g, 0.17 mmol, for 3 and 5,
respectively) and AgCF3SO3 (0.09 g, 0.37 mmol; 0.05 g, 0.21 mmol,
for 3 and 5, respectively). After a 6 or 7 h reflux (for 3 or 5,
respectively) the reaction mixture was cooled to room temperature
and filtered, and the solvent was removed under vacuum. The dark
orange residue was recrystallized from dichloromethane/n-hexane,
originating 3, or recrystallized three times from dichloromethane/n-
hexane, originating 5, in 87 and 56% yield, respectively. Single crystals
were isolated by recrystallization from dichloromethane/n-hexane for
compounds 3 and 5.
Complex 3. 87% yield. Dark orange powder. 1H NMR
[(CD3)2CO, Me4Si, δ/ppm]: 9.53 (d, 2,
3JHH = 8.0, H1); 8.25 (d,
2, 3JHH = 8.0, H4); 7.93 (t, 2,
3JHH = 8.0, H3); 7.38 (t, 2,
3JHH = 8.0,
H2); 7.14 (m, 12, P(PhF)3); 4.96 (s, 5, η
5-C5H5).
13C{1H} NMR
[(CD3)2CO, δ /ppm]: 164.7 (dd,
1JCF = 250.5;
4JCP = 2.0, Cq,
P(PhF)3); 157.4 (d,
3JCP = 2.0, C1); 156.6 (C5); 137.3 (C3); 136.2
(dd, 3JCP = 12.6;
2JCF = 8.0, CHmeta P(PhF)3); 128.5 (dd,
1JCP = 43.3;
4JCF = 3.0, Cq, P(PhF)3); 126.3 (C2); 124.3 (C4); 116.6 (dd,
2JCP =
21.1; 3JCF = 11.1, CHorthoP(PhF)3); 79.6 (d,
2JCP = 3.0, Cp).
31P{1H}
NMR [(CD3)2CO, δ/ppm]: 50.40 (s, P(PhF)3). UV−vis [CH2Cl2,
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λmax/nm (ε × 103/M−1cm−1)]: 290 (25.5); 342 (6.2); 418 (4.6); 473
(Sh). [DMSO, λmax/nm (ε × 103/M−1cm−1)]: 293 (22.2); 352 (Sh);
414 (4.0); 472 (Sh). FTIR [KBr, cm−1]: 3075 (υC−H Cp and aromatic
rings); 1587, 1495 (υCC Cp and aromatic rings); 1257 (υ-
(CF3SO3
−)). Anal Calcd for C34H25F6N2O3PRuS (787.68): C, 51.9;
H, 3.2; N, 3.6; S, 4.1. Found: C, 51.9; H, 3.3; N, 3.5; S, 4.0.
Complex 5. 56% yield. Dark orange powder. 1H NMR
[(CD3)2CO, Me4Si, δ/ppm]: 9.52 (d, 2,
3JHH = 4.0, H1); 8.18 (d,
2, 3JHH = 8.0, H4); 7.89 (t, 2,
3JHH = 8.0, H3); 7.33 (m, 2, H2); 7.01
(m, 6, HorthoP(PhOCH3)3), 6.86 (m, 12, HmetaP(PhOCH3)3); 4.89 (s,
5, η5-C5H5); 3.81 (s, 9, OCH3).
13C{1H} NMR [(CD3)2CO, δ
/ppm]: 162.0 (d, 4JCP = 2.0, CqP(PhOCH3)3); 157.1 (d,
3JCP = 2.0,
C1); 156.6 (C5); 136.8 (C3); 135.2 (d,
2JCP = 12.1, CHorthoP-
(PhOCH3)3); 125.8 (C2); 124.2 (C4); 123.8 (d,
1JCP = 47.3, Cq,
P(PhOCH3)3); 114.7 (d,
3JCP = 10.1, CHmetaP(PhOCH3)3); 79.1 (d,
2JCP = 3.0, Cp); 55.7 (OCH3).
31P{1H} NMR [(CD3)2CO, δ/ppm]:
47.39 (s, P(PhOCH3)3). UV−vis [CH2Cl2, λmax/nm (ε × 103/
M−1cm−1)]: 245 (62.1); 290 (32.5); 352 (Sh); 429 (5.1); 494 (Sh).
[DMSO, λmax/nm (ε × 10
3/M−1cm−1)]: 293 (25.8); 355 (Sh); 425
(4.0); 468 (Sh). FTIR [KBr, cm−1]: 3094−2837 (υC−H Cp and
aromatic rings); 1593−1440 (υCC Cp and aromatic rings); 1262
(υ(CF3SO3
−)). Anal Calcd for C37H34F3N2O6PRuS (823.79): C,
54.0; H, 4.2; N, 3.4; S, 3.9. Found: C, 53.8; H, 4.1; N, 3.1; S, 4.0.
[Ru(η5-C5H5)(P(C6H4R)3)(bipy−biotin)][CF3SO3] (R = F, 4; R =
OCH3, 6). To a stirred and degassed solution of 1 or 2 (0.15 g, 0.18
mmol; 0.33 g, 0.36 mmol, for 4 and 6, respectively) in methanol (40
mL) were added bipy−biotin (0.15 g, 0.22 mmol; 0.20 g, 0.30 mmol,
for 4 and 6, respectively) and AgCF3SO3 (0.07 g, 0.27 mmol; 0.12 g,
0.46 mmol, for 4 and 6, respectively). After a 4 or 7 h reflux (for 4 and
6, respectively), the reaction mixture was cooled to room temperature
and filtered, and the solvent was removed under vacuum. The orange
residue was recrystallized twice from methanol/diethyl ether,
originating 4, or three times from dichloromethane/n-hexane,
originating 6, in 59 and 52% yield, respectively.
Complex 4. 59% yield. Orange powder. 1H NMR [(CD3)2CO,
Me4Si, δ/ppm]: 9.51 (d, 2,
3JHH = 4.0, H1); 8.21 (s, 2, H4); 7.40 (d, 2,
3JHH = 8.0, H2); 7.15 (m, 12, P(PhF)3); 6.34 (d, 2,
3JHH = 16.0, NH);
6.08 (s, 2, NH); 5.25 (m, 4, H6); 4.97 (s, 5, η
5-C5H5); 4.49 (m, 2,
H13); 4.33 (m, 2, H12); 3.21 (m, 2, H11); 2.91 (under the solvent
signal, H14); 2.68 (m, 2, H14); 2.50 (m, 4, H7); 1.72 (m, 4, H8); 1.62
(m, 4, H10); 1.47 (m, 4, H9).
13C{1H} NMR [(CD3)2CO, δ /ppm]:
173.5 (CO ester); 164.7 (dd, 1JCF = 249.5; 4JCP = 2.0, Cq,
P(PhF)3); 164.3 (d, CO biotin); 157.1 (C1); 156.3 (d, C5); 147.8
(d, C3); 136.2 (dd,
3JCP = 13.0;
2JCF = 8.0, CHmetaP(PhF)3); 128.3
(dd, 1JCP = 43.3;
4JCF = 4.0, Cq, P(PhF)3); 124.7 (d, C2); 122.5 (d,
C4); 116.7 (dd,
2JCP = 21.6;
3JCF = 11.1, CHorthoP(PhF)3); 79.6 (d,
2JCP = 2.0, Cp); 64.1 (d, C6); 62.5 (d, C12); 60.9 (C13); 56.6 (d, C11);
41.1 (d, C14); 34.1 (d, C7); 29.1 (under the signal of the solvent, C9,
C10); 25.5 (d, C8).
31P{1H} NMR [(CD3)2CO, δ/ppm]: 50.17 (s,
P(PhF)3). UV−vis [CH2Cl2, λmax/nm (ε × 103/M−1cm−1)]: 294
(21.1); 338 (Sh); 424 (3.9); 489 (Sh). [DMSO, λmax/nm (ε × 103/
M−1cm−1)]: 296 (22.2); 341 (Sh); 420 (4.3); 479 (Sh). FTIR [KBr,
cm−1]: 3240 (υNH amine); 3071 (υC−H Cp and aromatic rings); 2930,
2860 (υC−H alkanes); 1732 (υCO ester); 1697 (υCO ketone); 1495
(υCC Cp and aromatic rings); 1260 (υ(CF3SO3−)); 1159 (υC−O
ester); 1030 (υC−N amine). Anal Calcd for C56H57F6N6O9PRuS3
(1300.32): C, 51.7; H, 4.4; N, 6.5; S, 7.4. Found: C, 51.2; H, 4.4;
N, 6.2; S, 7.0.
Complex 6. 52% yield. Orange powder. 1H NMR [(CD3)2CO,
Me4Si, δ/ppm]: 9.50 (d, 2,
3JHH = 4.0, H1), 8.12 (s, 2, H4), 7.35 (d, 2,
3JHH = 8.0, H2), 7.01 (m, 6, HorthoP(PhOCH3)3), 6.86 (m, 6,
HmetaP(PhOCH3)3), 6.29 (s, 2, NH), 6.04 (d, 2,
3JHH = 4.0, NH), 5.25
(m, 4, H6), 4.90 (s, 5, η
5-C5H5), 4.49 (m, 2, H13), 4.32 (m, 2, H12),
3.82 (s, 9, OCH3), 3.22 (m, 2, H11), 2.87 (under the solvent signal,
H14), 2.69 (m, 2, H14), 2.50 (m, 4, H7), 1.71 (m, 4, H8), 1.63 (m, 4,
H10), 1.48 (m, 4, H9).
13C{1H} NMR [(CD3)2CO, δ /ppm]: 173.6
(d, CO ester); 164.2 (d, CO biotin); 162.07 (4JCP = 2.0, Cq,
P(PhOCH3)3); 157.0 (C1); 156.4 (d, C5); 147.2 (d, C3); 135.4 (d,
2JCP = 13.1, CHorthoP(PhOCH3)3); 124.3 (d, C2); 123.7 (d,
1JCP =
46.3, Cq, P(PhOCH3)3); 122.4 (d, C4); 114.8 (d,
3JCP = 11.1,
CHmetaP(PhOCH3)3); 79.2 (d,
2JCP = 2.0, Cp); 64.2 (d, C6); 62.6 (d,
C12); 60.9 (d, C13); 56.7 (d, C11); 55.8 (OCH3); 41.2 (d, C14); 34.2
(d, C7); 29.2 (under the signal of the solvent, C9, C10); 25.6 (C8).
31P{1H} NMR [(CD3)2CO, δ/ppm]: 47.13 (s, P(PhOCH3)3). UV−
vis [CH2Cl2, λmax/nm (ε × 10
3/M−1cm−1)]: 246 (51.8); 295 (22.5);
332 (6.6); 437 (3.8); 488 (Sh). [DMSO, λmax/nm (ε × 10
3/
M−1cm−1)]: 296 (22.6); 340 (Sh); 432 (3.7); 480 (Sh). FTIR [KBr,
cm−1]: 3360 (υNH amine); 3073 (υC−H Cp and aromatic rings); 2932,
2860 (υC−H alkanes); 1732 (υCO ester); 1703 (υCO ketone); 1499
(υCC Cp and aromatic rings); 1253 (υ(CF3SO3−)); 1155 (υC−O
ester); 1030 (υC−N amine). ESI-MS (+): calcd for [6]
+, m/z 1187.31;
found, m/z: 1087.21.
X-ray Crystal Structure Determination. Three-dimensional X-
ray data were collected on a Bruker Kappa Apex CCD diffractometer
at low temperature for the compounds 2, 3, 5, and LCR134′, by the
ϕ−ω scan method. Reflections were measured from a hemisphere of
data collected from frames, each of them covering 0.3° in ω. A total of
63736 for 2, 45359 for 3, 48457 for 5, and 142051 for LCR134′
reflections measured were corrected for Lorentz and polarization
effects and for absorption by multiscan methods based on symmetry-
equivalent and repeated reflections. Of the total, 6448 for 2, 5984 for
3, 6550 for 5 and 12715 for LCR134′, independent reflections
exceeded the significance level (|F|/σ|F|) > 4.0. After data collection,
in each case an multiscan absorption correction (SADABS)54 was
applied, and the structure was solved by direct methods and refined
by full matrix least-squares on F2 data using SHELX suite of
programs.55 Olex2 program was used in the refinement of LCR134′.56
Hydrogen atoms were included in calculation position and refined in
the riding mode for all structures. Refinements were done with
allowance for thermal anisotropy of all non-hydrogen atoms. A final
difference Fourier map showed no residual density outside: +0.949
and −0.944 e·Å−3 for 2, +0.538 and −0.583 e·Å−3 for 3, +0.368 and
−0.421 e·Å−3 for 5 and +1.09 and −0.81 e·Å−3 for LCR134′. A
weighting scheme w = 1/[σ2(Fo
2) + (0.091800P)2 + 0.00000P] for 2,
1/[σ2(Fo
2) + (0.033800P)2 + 0.842800P] for 3, 1/[σ2(Fo
2) +
(0.024400P)2 + 2.362200P] for 5, and 1/[σ2(Fo
2) + (0.142933P)2
+ 0.000000P] for LCR134′, where P = (|Fo|2 + 2|Fc|2)/3, were used in
the latter stages of refinement. Disordered CF3SO3
− and Cl− anions
appear in the crystal packing of LCR134′. These disorders have been
refined and two atomic sites for the trifluoromethanesulfonic ion and
other two atomic sites for the chlorine atom have been observed and
refined with the anisotropic atomic displacement parameters. The site
occupancy factors were 0.536761 for S(1A)−O(1A)−F(1A)−C-
(1A)−O(2A)−F(2A)−O(3A)−F(3A) of the CF3SO3− anion and
0.526463 for Cl(2A) of the Cl− anion. A part of one ring of bipyridine
molecule is disordered too. The site occupancy factor was 0.279972
for C(6A)−C(7A). Further details of the crystal structures
determination are given in Tables S7−S8. CCDC 1900479−
1900482 contain the supplementary crystallographic data for the
structures reported in this paper.
Stability Studies in DMSO/DMEM. For the stability studies, all
complexes were dissolved in 5% DMSO/95% DMEM at ca. 1 × 10−4
M, and their electronic spectra were recorded in the range allowed by
the solvents at set time intervals. The samples used in the
measurements were protected from light sources and were stored at
room temperature between measurements.
Biological Evaluation. Cell Lines and Culture Conditions.
MCF7 and MDA-MB-231 cells were grown at 37 °C in 5% CO2 in
Dulbecco’s modified Eagles’s medium (DMEM high glucose)
(Capricorn Scientific) supplemented with 10% fetal bovine serum
(Capricorn Scientific) and 1% penicillin/streptomycin (Capricorn
Scientific). All cells were adherent in monolayers and, upon
confluence, were washed with phosphate buffer saline (PBS) 1×
and harvested by digestion with trypsin 0.05% (v/v). Trypsin was
inactivated by adding fresh complete culture media to the culture
flask. Cells were then suspended and transferred into new, sterile,
culture flasks or seeded in sterile test plates for the different assays. All
cells were manipulated under aseptic conditions in a flow chamber.
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Compounds Dilution and Storage. All compounds were dissolved
in 100% DMSO and divided in aliquots of 10 μL each. Afterward,
they were stored at −20 °C until use.
Compound Cytotoxicity Evaluated by MTT Assay. The cells were
adherent in monolayers and, upon confluency, were harvested by
digestion with trypsin−EDTA. The cytotoxicity of the complexes
against the tumor cells was assessed using the colorimetric assay MTT
(3-(4,5-2-yl)-2,5-ditetrazolium bromide), which measures the con-
version of the yellow tetrazolium into purple formazan by
mitochondrial redox activity in living cells. For this purpose, cells
((10−20) × 103 in 200 μL of medium) were seeded into 96-well
plates and incubated in a 5% CO2 incubator at 37 °C. Cells settled for
24 h followed by the addition of a dilution series of the complexes in
medium (200 μL). The complexes and ligands were first solubilized in
100% DMSO, given a 10 mM stock solution, then in medium within
the concentration range 0.01−100 μM for the complexes and 10−200
μM for phosphane- and bipyridine-based ligands. DMSO did not
exceed 1% even for the higher concentration used, and it was without
cytotoxic effect. After 24 h of incubation, the treatment solutions were
removed by aspiration, and MTT solution (200 μL, 0.5 mg/mL in
PBS) was added to each well. After 3−4 h at 37 °C/5% CO2, the
solution was removed, and the purple formazan crystals formed inside
the cells were dissolved in DMSO (200 μL) by thorough shaking. The
cellular viability was evaluated by measuring the absorbance at 570
nm by using a microplate spectrophotometer.
Compound Cytotoxicity Evaluated by SRB Assay. MDA-MB-231
cells were seeded at a concentration of 4 × 104 cells/mL, in 24-well
test plates. After 24 h of seeding, cells were incubated with different
concentrations of the LCR134, 4, and 6 compounds for 48 h. For
each cell line and compound, two negative controls were performed, a
control (1) in which cells were incubated only with growth medium
and a DMSO control (2) in which the cells were exposed to the
highest concentration used of DMSO (maximum of 0.1% DMSO per
well (v/v)), to discard any influence of this solvent in the results. After
a 48 h treatment, cells were fixed in ice-cold methanol containing 1%
acetic acid for at least 90 min at −20 °C. Fixing solution was then
removed, and the plate was left air-dry at room temperature; then, the
fixed cells were incubated with 0.5% (w/v) SRB dissolved in 1% acetic
acid for 90 min at 37 °C protected from light. After washing with 1%
acetic acid and air-drying at room temperature, SRB was solubilized
with 10 mM Tris pH 10. Absorbance was read at 540 nm in a
microplate spectrophotometer (Bio Tek Synergy HT). Results were
expressed relatively to the negative control (1), which was considered
as 100% of cell growth.
Biotin−Avidin Interaction Assay. The biotin−avidin interactions
of the compounds 3 and 5, bearing 2,2′-bipyridine ligand and the
biotinylated complexes 4, 6, and LCR134 were measured by using a
Pierce Biotin Quantitation kit (ThermoScientific) according to the
manufacturer’s protocol. For this purpose, 100 μL of MQ water was
added to each tube of HABA/Avidin premix, after it was equilibrated
at room temperature. Then, 160 μL of PBS was added to each
microplate well, followed by addition of 20 μL of HABA/Avidin
premix solution. The microplate was placed in a microplate
spectrophotometer, mixed and the absorbance measured at 500 nm.
After recording the absorbance values, 20 μL of complexes 3−6 and
LCR134 or biotin (positive control), at a concentration of 10 μM,
were added to the well containing the HABA/Avidin mixture and
mixed. The absorbance values were measured again at 500 nm from
time to time, until values remained constant. A solution containing
0.1% DMSO or water were used as negative controls.
Cellular Uptake Measured by ICPMS Analysis. For the cellular
uptake experiments, MDA-MB-231 and MCF7 cells (ca. 1 × 106 and
2 × 106 cells, respectively in 5 mL medium) were seeded into t25
flasks and incubated in a 5% CO2 incubator at 37 °C. Cells settled for
24 h, followed by the addition of LCR134, 4, and 6 at a concentration
equivalent to their IC50 values found for 24 h challenge at 37 °C. After
incubation, cells were washed with ice-cold PBS and treated in order
to obtain a cellular pellet. The cytosol, membrane/particulate,
cytoskeletal, and nuclear fractions were extracted using a Fraction-
PREP (BioVision, USA) cell fractionation kit according to the
manufacturer’s protocol. The Ru (101Ru) content in each fraction was
measured by a Thermo X-Series Quadrupole ICPMS (Thermo
Scientific) after digestion of the samples and using the same
procedure previously described.47
Cell Death Measurement by Flow Cytometry−Annexin V/PI
Assay. After a 48 h treatment with compounds LCR134, 4, and 6,
both suspended and attached cells were collected and washed in 1×
PBS. Then 1 × 106 cells were resuspended in 100 μL of 1× binding
buffer and incubated with 5 μL AV- fluorescein isothiocyanate (BD
Biosciences, San Jose, CA) and 5 μL of PI (50 μg/mL) for 15 min in
the dark. Samples were analyzed using CytoFLEX Cytometer
(Beckman Coulter) in an Epics XLTM (Beckman Coulter)
cytometer, equipped with an argon-ion laser emitting a 488 nm
beam at 15 mW. Monoparametric detection of red fluorescence was
performed using FL-4 (488/675 nm) and detection of green
fluorescence was performed using FL-1 (488/525 nm). Then
20 000 cells were analyzed per sample, and data were analyzed
using FlowJo software (version 7.6, Tree Star Inc., Ashland, OR).
Colony Formation Assay. MDA-MB-231 were seeded in 6-well
plates at 300 cells/mL. Then, 24 h after plating, cells were incubated
with 1/4 IC50 and IC50 values of compounds LCR134, 4, and 6. 48 h
after the incubation, old medium was removed, and cells were
incubated with fresh medium. Medium was renewed every 3 days.
Eleven days after removing the treatments, cells were washed with
PBS and incubated in a solution of glutaraldehyde (6% (v/v)) with
crystal violet (0.5% (w/v)) for at least half an hour. The plate was
washed with fresh water and left air-dry. Colonies were counted
manually. The negative control was incubated with the correspondent
volume of DMSO used in the solubilization of the compounds
(vehicle), and the final concentration of DMSO per well did not
exceed 0.1%.
In Vivo Toxicity Assessment Using Zebrafish Embryos. The AB
strain zebrafish (Zebrafish International Resource Center, Eugene,
OR) was used for all experiments. Breeding stocks were bred and
housed in Aquatic Habitats (Apopka, FL) recirculating systems under
a 14/10 h light/dark cycle. System water was obtained by carbon/
sand filtration of municipal tap water and water quality was
maintained at <0.05 ppm nitrite, < 0.2 ppm ammonia, pH between
7.2 and 7.7, and water temperature between 26 and 28 °C. All
experiments were conducted in accordance with the zebrafish
husbandry protocol and embryonic exposure protocol (#08−025)
approved by the Rutgers University Animal Care and Facilities
Committee.
Males and females were maintained separately and comingled the
night before to allow spawning the next morning. Spawning substrates
were placed into the fish tanks on the day prior to spawning. In case
eggs were obtained from more than one set of breeders, all eggs that
were fertilized and progressing normally through development were
mixed.
Zebrafish embryos were exposed to different concentrations of
compounds 3, 4, 5, and 6 (Table 3), at 0.05% of DMSO in individual
glass vials through a waterborne exposure from 3 h postfertilization
(hpf) until 120 hpf (5 days) in a static nonrenewal protocol. The
solutions were prepared from compound 3, 4, 5, and 6 stock solution
of 7.79, 115.80, 5.30, and 92.56 mg/L, respectively.
The exposure followed a modified OECD 236 protocol,50 where
the end points of lesion presence, length, and mortality were recorded,
during the major stages of organ development and the toxicological
estimates (LC50, NOEC, LOEC and NOAEL) were determined.
Those embryos surviving at the end of the toxicological experiment
(120 hpf) were used for both morphological data and ICPMS Ru
quantification analysis. For morphological data, approximately 12
individual larvae from each complex concentration and control group
were fixed in formalin and then stained for bone and cartilage
following a two-color acid free Alcian blue/Alizarin red stain.57
Photographs were taken using a Scion digital camera model CFW-
1310C mounted on an Olympus SZ-PT dissecting microscope, and
cartilage/bone were measured using Adobe Photoshop. End points
examined included total body length, intraocular distance, and yolk
sac and pericardial sac size to assess larval growth, cranial facial
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development, and nutrient storage and usage, respectively (Figures
S4−S7). For the analytical data, the solutions in each vial were
collected for ICPMS analysis, and the larvae were euthanized and
fixed with 10% buffered formalin phosphate.58 Three replicates
containing larvae from each concentration were also collected for
ICPMS analysis (see below).
The concentrations of each individual compounds and correspond-
ing control groups were set up as individual experiments, and the
sample size was between 30 and 40 embryos, and repeated two times.
The controls had ≥90% survival rate.
Quantification of Ruthenium Element by Inductively Coupled
Plasma Mass Spectrometry (ICPMS). Samples were quantified via
high resolution ICPMS (Nu Instruments Attom, U.K.) at Rutgers
EOHSI Analytical Facility. The instrument settings for the ICPMS are
provided in Table 4. Larval samples were microwave digested using a
MARS X microwave digester (CEM Matthews NC) in OmniTrace
Nitric acid and diluted to 3.5% acid with 30% hydrogen peroxide
solution (Sigma-Aldrich). Spiked egg water treatments were acidified
to 3.5%. The samples were introduced through a ASX-500 Model 510
Auto Sampler (Cetac) and into a Gass Expansion Conikal Nebulizer
within the Peltier cooling system. Data was sent into the Attom
software (Attolab v.1) and analyzed with NuQuant by using a seven-
point calibration curve. The limit of quantification for these samples
was 0.005 ppb and ruthenium isotopes 99, 100, 101, and 102 were
quantified. It is important to note that an oxide of strontium, an
ingredient in salt water solutions, like egg water, has considerable
isobaric interference for ruthenium 100. No isobaric interferences
were noted for larval samples. The ruthenium concentrations given by
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Table 3. Analytically Evaluated Concentrations by ICPMS
at the End of the Experiment (120 hpf Experiment)a
complex solutions (mg/L) std larvae (ng/embryo) std
3 ND (control) − ND (control) −
0.69 0.16 1.56 0.40
2.02 0.26 3.37 0.74
3.18 0.41 4.93 0.70
3.57 0.26 − −
4 ND (control) − ND (control) −
1.31 0.08 1.89 0.79
1.79 0.08 1.93 0.23
2.03 0.21 3.79 1.03
2.44 0.42 − −
2.56 0.29 − −
8.77 0.58 − −
19.19 0.23 − −
5 ND (control) − ND (control) −
0.02 0.01 0.23 0.08
0.04 0.01 0.49 0.08
0.17 0.03 0.92 0.12
0.57 0.05 3.57 1.57
0.92 0.20 − −
1.20 0.27 − −
1.36 0.11 − −
6 ND (control) − ND (control) −
0.63 0.12 0.86 0.12
0.80 0.13 1.17 0.10
1.52 0.40 − −
3.01 0.54 − −
aThe ruthenium (element) concentrations given by ICPMS in μg/L
(ppb) were converted to concentrations of each complex, in mg/L or
ng/embryo. ND: Not detected.
Table 4. ICPMS Method Parameters
method settings parameter
analysis mode deflector jump, single mass jump
dwell time per peak 4 ms
switch delay per peak (×10 μs) 2
number of sweeps 450
number of cycles 1
instrument resolutuion 300
scan window (%) 0
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A.; et al. New Derivatives of Vitamin B12 Show Preferential Targeting
of Tumors. Cancer Res. 2008, 68 (8), 2904−2911.
(3) Paulos, C. M.; Turk, M. J.; Breur, G. J.; Low, P. S. Folate
Receptor-Mediated Targeting of Therapeutic and Imaging Agents to
Activated Macrophages in Rheumatoid Arthritis. Adv. Drug Delivery
Rev. 2004, 56 (8), 1205−1217.
(4) Russell-Jones, G.; McTavish, K.; McEwan, J.; Rice, J.; Nowotnik,
D. Vitamin-Mediated Targeting as a Potential Mechanism to Increase
Drug Uptake by Tumours. J. Inorg. Biochem. 2004, 98 (10), 1625−
1633.
(5) Ren, W. X.; Han, J.; Uhm, S.; Jang, Y. J.; Kang, C.; Kim, J. H.;
Kim, J. S. Recent Development of Biotin Conjugation in Biological
Imaging, Sensing, and Target Delivery. Chem. Commun. 2015, 51
(52), 10403−10418.
(6) Collina, S.; Tripodo, G.; Mandracchia, D.; Rui, M.; Rossi, D.
New Perspectives in Cancer Therapy: The Biotin-Antitumor
Molecule Conjugates. Med. Chem. (Los. Angeles) 2014, S1 (4), 1−8.
(7) Chen, S.; Zhao, X.; Chen, J.; Chen, J.; Kuznetsova, L.; Wong, S.
S.; Ojima, I. Mechanism-Based Tumor-Targeting Drug Delivery
System. Validation of Efficient Vitamin Receptor-Mediated Endocy-
tosis and Drug Release. Bioconjugate Chem. 2010, 21 (5), 979−987.
(8) Lis, L. G.; Smart, M. A.; Luchniak, A.; Gupta, M. L.; Gurvich, V.
J. Synthesis and Biological Evaluation of a Biotinylated Paclitaxel with
an Extra-Long Chain Spacer Arm. ACS Med. Chem. Lett. 2012, 3 (9),
745−748.
(9) Singh, Y.; Durga Rao Viswanadham, K. K.; Kumar Jajoriya, A.;
Meher, J. G.; Raval, K.; Jaiswal, S.; Dewangan, J.; Bora, H. K.; Rath, S.
K.; Lal, J.; et al. Click Biotinylation of PLGA Template for Biotin
Receptor Oriented Delivery of Doxorubicin Hydrochloride in 4T1
Cell-Induced Breast Cancer. Mol. Pharmaceutics 2017, 14 (8), 2749−
2765.
(10) Maiti, S.; Park, N.; Han, J. H.; Jeon, H. M.; Lee, J. H.; Bhuniya,
S.; Kang, C.; Kim, J. S. Gemcitabine-Coumarin-Biotin Conjugates: A
Target Specific Theranostic Anticancer Prodrug. J. Am. Chem. Soc.
2013, 135 (11), 4567−4572.
(11) Hu, W.; Fang, L.; Hua, W.; Gou, S. Biotin-Pt (IV)-
Indomethacin Hybrid: A Targeting Anticancer Prodrug Providing
Enhanced Cancer Cellular Uptake and Reversing Cisplatin Resistance.
J. Inorg. Biochem. 2017, 175 (June), 47−57.
(12) Trondl, R.; Heffeter, P.; Kowol, C. R.; Jakupec, M. A.; Berger,
W.; Keppler, B. K. NKP-1339, the First Ruthenium-Based Anticancer
Drug on the Edge to Clinical Application. Chem. Sci. 2014, 5 (8),
2925−2932.
(13) Alessio, E.; Messori, L. The Deceptively Similar ruthenium(III)
Drug Candidates KP1019 and NAMI-A Have Different Actions. What
Did We Learn in the Past 30 Years? Met. Ions Life Sci. 2018, 18, 141−
170.
(14) Jakupec, M. A.; Kandioller, W.; Schoenhacker-Alte, B.; Trondl,
R.; Berger, W.; Keppler, B. K. Trends and Perspectives of Ruthenium
Anticancer Compounds (Non-PDT). Ruthenium Complexes: Photo-
chemical and Biomedical Applications 2017, 271−291.
(15) Murray, B. S.; Babak, M. V.; Hartinger, C. G.; Dyson, P. J. The
Development of RAPTA Compounds for the Treatment of Tumors.
Coord. Chem. Rev. 2016, 306 (P1), 86−114.
(16) Dougan, S. J.; Sadler, P. J. The Design of Organometallic
Ruthenium Arene Anticancer Agents. Chimia 2007, 61 (11), 704−
715.
(17) Morais, T. S.; Valente, A.; Tomaz, A. I.; Marques, F.; Garcia, M.
H. Tracking Antitumor Metallodrugs: Promising Agents with the
Ru(II)- and Fe(II)-Cyclopentadienyl Scaffolds. Future Med. Chem.
2016, 8 (5), 527−544.
(18) Scalambra, F.; Lorenzo-Luis, P.; de los Ríos, I.; Romerosa, A.
New Findings in Metal Complexes with Antiproliferative Activity
Containing 1,3,5-Triaza-7-Phosphaadamantane (PTA) and Derivative
Ligands. Eur. J. Inorg. Chem. 2019, 2019, 1529−1538.
(19) Gano, L.; Pinheiro, T.; Matos, A. P.; Tortosa, F.; Jorge, T. F.;
Gonca̧lves, M. S.; Martins, M.; Morais, T. S.; Tomaz, A. I.; Valente,
A.; et al. Antitumour and Toxicity Evaluation of a Ru(II)-
Cyclopentadienyl Complex in a Prostate Cancer Model by Imaging
Tools. Anticancer. Agents Med. Chem. 2019, DOI: 10.2174/
1871520619666190318152726.
(20) Mendes, N.; Tortosa, F.; Valente, A.; Marques, F.; Matos, A.;
Morais, T. S.; Tomaz, A. I.; Gar̈tner, F.; Garcia, M. H. In Vivo
Performance of a Ruthenium-Cyclopentadienyl Compound in an
Orthotopic Triple Negative Breast Cancer Model. Anticancer. Agents
Med. Chem. 2017, 17, 126−136.
(21) Babak, M. V.; Plazuk, D.; Meier, S. M.; Arabshahi, H. J.;
Reynisson, J.; Rychlik, B.; Błauz, A.; Szulc, K.; Hanif, M.; Strobl, S.;
et al. Half-Sandwich Ruthenium(II) Biotin Conjugates as Biological
Vectors to Cancer Cells. Chem. - Eur. J. 2015, 21 (13), 5110−5117.
(22) Siewert, B.; Langerman, M.; Pannwitz, A.; Bonnet, S. Synthesis
and Avidin Binding of Ruthenium Complexes Functionalized with a
Light-Cleavable Free Biotin Moiety. Eur. J. Inorg. Chem. 2018, 2018
(37), 4107.
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Sanches, A.; Robalo, M. P.; Avecilla, F.; Moreira, T.; Garcia, M. H.;
Haukka, M.; et al. Novel Ruthenium Methylcyclopentadienyl
Inorganic Chemistry Article
DOI: 10.1021/acs.inorgchem.9b00735
Inorg. Chem. 2019, 58, 9135−9149
9148
Complex Bearing a Bipyridine Perfluorinated Ligand Shows Strong
Activity towards Colorectal Cancer Cells. Eur. J. Med. Chem. 2018,
143, 503−514.
(33) Moreno, V.; Font-Bardia, M.; Calvet, T.; Lorenzo, J.; Avileś, F.
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